HU900222D0 - Process for giving 5b-10, 45rh-103 isotops to ferrofluidic ferric oxide, advantageous stopping vital functions of cancerous cells - Google Patents

Process for giving 5b-10, 45rh-103 isotops to ferrofluidic ferric oxide, advantageous stopping vital functions of cancerous cells

Info

Publication number
HU900222D0
HU900222D0 HU90222A HU22290A HU900222D0 HU 900222 D0 HU900222 D0 HU 900222D0 HU 90222 A HU90222 A HU 90222A HU 22290 A HU22290 A HU 22290A HU 900222 D0 HU900222 D0 HU 900222D0
Authority
HU
Hungary
Prior art keywords
iron oxide
isotope
fine grain
carrier medium
grain iron
Prior art date
Application number
HU90222A
Other languages
Hungarian (hu)
Inventor
Peter Teleki
Original Assignee
Peter Teleki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peter Teleki filed Critical Peter Teleki
Priority to HU90222A priority Critical patent/HU900222D0/en
Priority to AU54234/90A priority patent/AU5423490A/en
Priority to PCT/HU1990/000024 priority patent/WO1991010452A1/en
Publication of HU900222D0 publication Critical patent/HU900222D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention refers to a method of preparing an iron oxide composition and an iron oxide composition for therapeutic treatment of a living body. The method comprises the steps of providing fine grain iron oxide, introducing the fine grain iron oxide into a liquid carrier medium applicable for therapeutic purposes and dispersing the fine grain iron oxide in the liquid carrier medium, including the novel step of completing the fine grain iron oxide with at least one isotope of low activity for a period sufficient for introducing the fine grain iron oxide into an organ targeted of the living body or at least one isotope capable of being activated by neutrons and decaying after the period or transforming under influence of the neutrons to a high activity isotope of short life time before transforming into a stable isotope. The composition as proposed comprises a liquid carrier medium, the liquid carrier medium being applicable in a living body and fine grain iron oxide made of at least one iron oxide selected from the group consisted of ferrous oxide, ferric oxide and ferroferric oxide forming a dispersion in the liquid carrier medium, wherein the fine grain iron oxide constitutes a solid carrier medium for bearing at least one isotope of low activity for a period sufficient for introducing the fine grain iron oxide into an organ targeted of the living body or at least one isotope capable of being activated by neutrons and decaying after the period or transforming under influence of the neutrons to an isotope of short life time radiating with high activity before transforming into a stable isotope, the stable isotope being not toxic.
HU90222A 1990-01-22 1990-01-22 Process for giving 5b-10, 45rh-103 isotops to ferrofluidic ferric oxide, advantageous stopping vital functions of cancerous cells HU900222D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
HU90222A HU900222D0 (en) 1990-01-22 1990-01-22 Process for giving 5b-10, 45rh-103 isotops to ferrofluidic ferric oxide, advantageous stopping vital functions of cancerous cells
AU54234/90A AU5423490A (en) 1990-01-22 1990-04-11 Improved method of preparing an iron oxide composition for therapeutic treatment of a living body and iron oxide composition
PCT/HU1990/000024 WO1991010452A1 (en) 1990-01-22 1990-04-11 Improved method of preparing an iron oxide composition for therapeutic treatment of a living body and iron oxide composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU90222A HU900222D0 (en) 1990-01-22 1990-01-22 Process for giving 5b-10, 45rh-103 isotops to ferrofluidic ferric oxide, advantageous stopping vital functions of cancerous cells

Publications (1)

Publication Number Publication Date
HU900222D0 true HU900222D0 (en) 1990-04-28

Family

ID=10948558

Family Applications (1)

Application Number Title Priority Date Filing Date
HU90222A HU900222D0 (en) 1990-01-22 1990-01-22 Process for giving 5b-10, 45rh-103 isotops to ferrofluidic ferric oxide, advantageous stopping vital functions of cancerous cells

Country Status (3)

Country Link
AU (1) AU5423490A (en)
HU (1) HU900222D0 (en)
WO (1) WO1991010452A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5061476A (en) * 1989-12-27 1991-10-29 The Dow Chemical Company Radiolabeled colloid compositions and method for preparing same
RU1837891C (en) * 1991-01-31 1993-08-30 Keshelava Viktor V Method for preparation antitumor agent
CA2080978A1 (en) * 1992-01-02 1993-07-03 Hans-Jurgen F. Sinn Retainer for a combined surgical needle shield with a needle tip stop feature

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057616A (en) * 1973-06-11 1977-11-08 Mallinckrodt, Inc. Metal hydroxide scintigraphic agents and method of preparation
US4303636A (en) * 1974-08-20 1981-12-01 Gordon Robert T Cancer treatment
US4071613A (en) * 1976-02-26 1978-01-31 Abbott Laboratories Stabilized alcohol solution of reducing salt formulations for use in preparing radioisotope labeled scanning agents: liver scanning technetium-99m colloid and method of preparation
US4752464A (en) * 1985-06-07 1988-06-21 Cadema Medical Products, Inc. Treatment of arthritis, including rheumatoid arthritis, with radioactive isotopes

Also Published As

Publication number Publication date
AU5423490A (en) 1991-08-05
WO1991010452A1 (en) 1991-07-25

Similar Documents

Publication Publication Date Title
IL144559A0 (en) Antibodies for cancer therapy and diagnosis
DK0683665T3 (en) Magnetically reactive composition as carrier for biologically active substances as well as methods for its preparation and use
AU663266B2 (en) Method for treating tumours
IL87885A0 (en) Compounds having antiprogestational and anti-estrogenic activities for the treatment of tumours
CA2346644A1 (en) Method for preventing xenograft transplant rejection using photodynamic therapy
EP0711300A4 (en) 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents
SG46496A1 (en) Tricyclopolyazamacrocyclophosphonic acids complexes and derivatives thereof for use as constrast agents
CA2133316A1 (en) In vitro generation of human dendritic cells and uses thereof
ES8201316A1 (en) Process for preparing lipoid-biologically active particles
EP1037531A4 (en) Method of treatment of pigmented cancer cells utilizing photodynamic therapy
EP0719150A4 (en) Cellular vaccine and methods of use for the treatment of solid tumor malignancies
CA2132001A1 (en) Methods of treating cancer using modified c-reactive protein
AU7655300A (en) Radiation source for endovascular radiation treatment in form of a wire
JPS57117868A (en) Method of combining biological active substance to carrier containing hydroxyl group
HU900222D0 (en) Process for giving 5b-10, 45rh-103 isotops to ferrofluidic ferric oxide, advantageous stopping vital functions of cancerous cells
KR930700163A (en) Methods of treating and / or diagnosing soft tissue tumors
CA2194485A1 (en) Endothelial lining effects and treatment of vasospastic disorders
HUT55642A (en) Process for producing surface therapy system containing antineoplasmatic agent expediently 5-fluoro-uracil
CA2327439A1 (en) Combination therapy for the treatment of tumors
PH23658A (en) Improved method of treating tumors with autologous lymphokine activated killer,interleukin-2 and an ornithine decarboxylase inhibitor
JPS5420193A (en) Immobilized aminoacylase and its preparation
JPS5221203A (en) Carbon-contained iron-base sintered alloy
JPS5265186A (en) Thermoluminescent composite fluorecent substances of oxide
JPS5257390A (en) Immobilized enzyme and method of preparing the same
JPS52138431A (en) Heat treatment of magnetic alloy of rare earths-cobalt line